Theolytics
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.
Theolytics has raised €5.5M across 2 funding rounds from 3 investors, most recently a Series A round in Jul 2021. Based in Oxford, UK; founded 2017; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€5.5M
€5,511,428
Funding rounds
2
Investors
3
distinct backers
Active since
2021-01
latest 2021-07
Funding by year
EUR raised per yearTheolytics — funding by year — interactive chart.
Data table
| Theolytics — funding by year | |
|---|---|
| 2021 | €5.5M |
Signals
Medium confidenceRaise-next likelihood8
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Exit likelihood8
base rate 11% (2+ rounds)
- ▲ 9y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-07-15 | Series A | — | M Ventures | View deal → |
| 2021-01-07 | Series A | €5.5M | Epidarex Capital,Taiho Ventures | View deal → |
Investors
3Related news
- Theolytics Expands Series A Funding Roundfinsmes.com · 2021-07
- finsmes.com
Similar companies
same sector or countryGlobal coverage: FundingData